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Introduction
Receptor tyrosine kinases (RTKs) are known to be key regulators 
of normal cellular processes such as differentiation, migration, 
proliferation and survival, but they also have a critical role in 
the development and progression of many types of human can-
cers. Consequently, RTKs and their ligands have become attrac-
tive molecular targets for therapeutic interventions of cancer. 
The ROR family of RTKs consists of two evolutionarily con-
served proteins, ROR1 and ROR21 and gene expression profiling 
identified ROR1 as one of the signature genes overexpressed in 
CLL.2,3 Subsequent reports showed a variety of cancer cell lines 
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and primary cancer cells of different histological origin expressed 
significant levels of ROR1 mRNA.4,5 Screening of the human 
kinome revealed ROR1 as one of the few potent survival kinases,6 
and siRNA-mediated silencing of ROR1 induced apoptosis 
in CLL cells.7 ROR1 protein levels increased following IL-6-
induced phosphorylation of a transcription factor, signal trans-
ducer and activator of transcription 3 (STAT-3), in myeloma 
cells, and overexpression of STAT-3, multiple Wnt genes and 
Wnt receptor Frizzled was observed in CLL cells.8 Unlike other 
RTKs, ROR1 is catalytically inactive and is transphosphory-
lated by the Met oncogene.5 Together, these findings suggest that 
ROR1 could provide survival signals and may contribute in the ©2 0 1 1   L a n d e s   B i o s c i e n c e .
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and 1A7-IgG), and the epitopes they recognized were determined 
by studying their reactivity against a panel of recombinant fusion 
proteins using ELISA (Fig. 1). All four mAbs exhibited strong 
binding to Fc-hROR1 and hROR1-ECD in a concentration-
dependent manner (range tested 10 μg/mL to 1.5 ng/mL, data 
shown for only 1 μg/mL), but not to human Fc, hROR2-Fc 
or BSA indicating their specific reactivity to purified hROR1. 
In addition, while both 2A2-IgG and 2D11-IgG were able to 
bind Fc-hROR1Ig+Fz, only 2A2-IgG bound to Fc-hROR1Ig 
and neither mAb bound to Fc-hROR1Fz, Fc-hROR1Kr or 
Fc-hROR1Fz+Kr proteins. This pattern of reactivity suggested 
that the epitope recognized by mAb 2A2 is likely located in the 
Ig domain of hROR1 and that of 2D11 mAb is shared between 
Ig and Fz domains. Conversely, both 1A1-IgG and 1A7-IgG 
were able to bind Fc-hROR1Fz+Kr and Fc-hROR1Kr, but not 
to Fc-hROR1Ig+Fz, Fc-hROR1Ig or Fc-hROR1Fz proteins, 
suggesting that the epitopes recognized by these two mAbs are 
likely located in the Kr domain of hROR1. As positive controls, 
GaROR1 pAbs demonstrated specific binding to all recombinant 
hROR1 proteins and GaROR2 pAbs to the recombinant hROR2 
protein (data not shown). In addition, the mAbs exhibited mod-
erate (2D11-IgG, 1A7-IgG) to strong (2A2-IgG, 1A1-IgG) cross-
reactivity to mouse ROR1 (Fc-mROR1). Overall, mAb 2A2 
exhibited stronger reactivity to hROR1 and mROR1 than the 
other three mAbs, which was confirmed by surface plasmon reso-
nance studies (see below and data not shown). This prompted 
us to focus on mAb 2A2 and clone, express and purify a mAb 
2A2-based immunotoxin in dsFv format we named BT-1 (see 
Materials and Methods and Fig. 2S). Like the parent mAb 2A2, 
BT-1 showed specific binding to hROR1-ECD in ELISA (OD 
405 value = 1.38) and did not bind hROR2-Fc (OD 405 value = 
0, i.e., equal to background).
Cell surface binding of anti-hROR1 mAbs and BT-1. Both 
2A2-IgG and 2D11-IgG exhibited dose-dependent (0.001–10 
μg/mL) binding to MCL cell lines JeKo-1, Mino and ex vivo 
primary CLL and MCL cells, but not to normal B cells or EBV-
transformed B-cell lines established from healthy donor PBMC 
(Fig. 2 and data not shown). By contrast, mAbs 1A1-IgG and 
1A7-IgG, despite binding to purified proteins in ELISA, did 
not show any binding to ROR1-positive cells or cell lines (data 
not shown), and further studies are needed to understand this   
discrepancy. In agreement with our previous report using 
GaROR1 pAbs,9 the binding of 2A2-IgG revealed variations in 
the level of ROR1 expression (differences in MFI) among sam-
ples from individual CLL patients and similarly, among samples 
from individual MCL patients (Fig. 2A and B). However, ROR1 
expression was uniform in all malignant B cells in each sample 
(Fig. S1). Subsequent studies showed that the binding was spe-
cific to the malignant cells (CD5+CD19+ cells) from CLL and 
MCL patients; other PBMC subpopulations in CLL and MCL 
patients or CD19-positive cells from healthy donors were not 
recognized (Fig. S1 and data not shown). Titration of 2A2-IgG 
showed significant binding at a concentration as low as 1 ng/mL 
(~6.5 pM), suggesting a high affinity/avidity interaction (data 
not shown). In addition, mAb 2A2-IgG bound to all MCL cell 
lines tested (HBL-2, JeKo-1, Mino and Rec-1), but not to Burkitt 
development of leukemia. Studies from our laboratory and others 
have demonstrated the uniform and restricted cell surface expres-
sion of ROR1 protein in CLL.9-11 We therefore hypothesized that 
ROR1 could serve as a target antigen for mAb based therapeutics.
B-cell malignancies are susceptible to therapeutic intervention 
by mAbs, and rituximab and ofatumumab, both of which target 
CD20 on all B cells (malignant and normal), and alemtuzumab, 
which targets CD52 on all leukocytes (malignant and normal), are 
FDA-approved for B-cell non-Hodgkin lymphoma (B-NHL) or 
CLL. Mechanistically, these three unarmed mAbs mediate direct 
cytotoxicity, complement dependent cytotoxicity (CDC) or anti-
body dependent cellular cytotoxicity (ADCC), and their efficacy 
depends on the availability of functional effector cells/molecules in 
the recipient. Although treatment with these mAbs has achieved 
significant progression-free survival and short-term overall survival 
benefits, most patients relapse or develop resistance. Therefore, 
there is a need for identification of new targets and development of 
novel therapeutics. In this context, mAbs against ROR1 would be 
welcome as they could specifically target malignant B cells, thereby 
sparing normal B cells and other leukocytes. Interestingly, patients 
with CLL produced endogenous anti-ROR1 antibodies following 
vaccination with CD40L-expressing autologous tumor cells,10 and 
following administration of the immunomodulatory drug lenalid-
omide,12 which upregulated CD40L expression in vitro. These 
observations suggest that antibodies directed against ROR1 per 
se may not cause any adverse events in vivo, although their con-
tribution to alleviate the disease remains to be understood. The 
restricted expression of cell surface ROR1 on malignant B cells 
and the apparent safety of an endogenous anti-ROR1 antibody 
response, prompted us to develop a ROR1-immunotoxin. Unlike 
unarmed mAbs, a ROR1-immunotoxin could specifically recog-
nize and kill the target cells independent of effector components 
(complement proteins, NK cells, macrophages or T cells) that 
may not be optimally available in cancer patients. Immunotoxins 
are fusion proteins consisting of a target antigen-binding moiety 
(a ligand or mAb) that confers specificity, and a toxin moiety 
(from a plant or bacterium) that mediates target cell killing.13,14 
Chemical conjugation of mAb and toxin has resulted in heteroge-
neous products unsuitable for clinical applications; this problem 
was overcome by genetic engineering wherein gene(s) encoding an 
antibody fragment are linked to a gene encoding selected toxin 
domains.14-18 A variety of immunotoxins with different antigen tar-
get specificities and different toxins have been developed to treat 
human cancers.19-22 We used truncated pseudomonas exotoxin A 
(PE38) because the functional domains of this toxin have been 
well characterized and the mechanisms of killing are known.16,23 
Several PE38-based immunotoxins have been developed and are 
currently in clinical trials for different human disease indications, 
including B-cell malignancies.20,24-27 We describe here the genera-
tion and functional characterization of the PE38-based immuno-
toxin BT-1 directed against ROR1.
Results
Specificity and epitope mapping of anti-hROR1 mAbs and 
BT-1. The specificity of mAbs (2A2-IgG, 2D11-IgG 1A1-IgG ©2 0 1 1   L a n d e s   B i o s c i e n c e .
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to the lack of an avidity gain in the former. Consequently, mon-
ovalent binding showed a significant decrease in the observed KD 
values (0.79 nM vs. 32.6 nM) with approximately 40-fold lower 
affinity (Table 1 and Fig. S3).
ROR1-immunotoxin BT-1 revealed a fast association rate 
similar to that seen with 2A2-IgG in binding Fc-hROR1. 
However, in comparison to bivalent 2A2-IgG, monovalent BT-1 
exhibited a more than 100-fold faster dissociation rate, result-
ing in an observed KD value of 64.9 nM (Table 1 and Fig. S3). 
Notably, the difference between the observed KD values of ana-
lytes 2A2-IgG and BT-1 was similar to that found for analytes 
Fc-hROR1 and hROR1-ECD, revealing the strong avidity gain 
conferred by bivalency when the antibody or the antigen was in 
solution phase.
ROR1-mediated internalization. Internalization of cell sur-
face bound anti-ROR1 mAb was measured as described before 
for pAbs.9 Both primary CLL cells and MCL cell lines exhibited 
partial internalization (approximately 30–45%) of cell surface 
bound 2A2-IgG (at 4°C) upon subsequent incubation at 37°C 
(Fig. 3A and B, and data not shown). Internalization was noticed 
as early as 30 min, reached a plateau by 2 h and no further 
increase was observed with prolonged incubation up to 6 h (data 
not shown). Internalization of cell surface bound mAbs was effi-
ciently blocked in the presence of a chemical inhibitor, PAO, dur-
ing incubation at 37°C (Fig. 3A and B). These results with mAbs 
are in agreement with our previous observation with GaROR1 
pAbs using primary CLL cells.9 A similar level of internalization 
was observed when biotinylated 2A2-IgG was used, although 
lymphoma cell lines (Raji, Ramos and Daudi), EBV-transformed 
B-cell lines (EBV-7475, RGC-EBV) or CLL cell lines (MEC-1, 
MEC-2 and 232-B4) (Fig. 2C and data not shown).
Similarly, like the parent mAb 2A2-IgG, immunotoxin BT-1 
showed dose dependent binding to primary CLL and MCL cells 
and to the MCL cell lines JeKo-1 and Mino (Fig. 2A, B and D). 
The binding of BT-1 was restricted to the CD5+/19+ subpopula-
tion in the PBMC samples from CLL and MCL patients (Fig. 2A 
and B). No significant binding above background was seen with 
B cells, T cells or other PBMC from healthy donors, and ROR1-
negative B-cell lines RGC-EBV, Daudi, Raji and Ramos (Fig. 2D 
and data not shown).
Kinetic and thermodynamic analysis of 2A2-IgG and BT-1 
binding to hROR1. To further investigate the affinity/avidity 
of 2A2-IgG and BT-1 in real time and label-free manner, we 
measured their interaction with hROR1 by surface plasmon res-
onance. First, hROR1-ECD or Fc-hROR1 (ligand) was immo-
bilized on a CM5 sensor chip and mAb 2A2-IgG was run in the 
mobile phase (analyte). Regardless of the monovalent (hROR1-
ECD) or bivalent (Fc-hROR1) nature of the ligand, 2A2-IgG 
showed a fast association (kon) followed by a slow dissociation 
(koff) resulting in observed equilibrium binding constants (KD) 
of 0.12 nM and 0.42 nM, respectively (Table 1 and Fig. S3). 
Next, in a reverse orientation, 2A2-IgG was captured as ligand 
on a CM5 chip, and hROR1-ECD or Fc-hROR1 were run as 
analytes. Whereas the association rates of the two analytes to the 
mAb did not differ much in this setting, monovalent hROR1-
ECD dissociated faster than bivalent Fc-hROR1, presumably due 
Figure 1. Specificity and epitope mapping of anti-hRoR1 mAbs. eLISA plates were coated with 100 ng/50 μL/well indicated recombinant fusion pro-
tein antigens. Different dilutions of mAbs 2A2-IgG (black bars), 2D11-IgG (open bars), 1A1-IgG (dark gray bars) or 1A7-IgG (light gray bars) were added 
(50 μL/well) and data obtained with 1 μg/mL alone is shown. the binding of the mAbs was detected using DaM-HRp as described in the Materials and 
Methods. Values represent arithmetic mean ± standard deviation of triplicates for each condition, and similar results were obtained in three indepen-
dent experiments. the data for Bt-1, and positive control pAbs (GaRoR1 and GaRoR2) are provided in the text.©2 0 1 1   L a n d e s   B i o s c i e n c e .
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indicating that internalization took place. Additional experi-
ments with another MCL cell line (Mino), as well as primary 
CLL and MCL cells showed similar levels of internalization of 
2A2-IgG (Fig. 3B and data not shown).
Internalization of cell surface bound immunotoxin is a key 
requirement for mediating cytotoxicity. Results showed that cell 
surface bound BT-1 disappeared in MCL cell lines, as well as 
in primary CLL and MCL cells, following incubation at 37°C 
(Fig. 3C and data not shown). However, given the weaker bind-
ing kinetics of BT-1 (Table 1), along with the observations that 
disappearance was greater (60–80%) than that of 2A2-IgG and 
not prevented by PAO (Fig. 3C), it is likely that dissociation con-
tributed to this disappearance. Nonetheless, a small amount of 
internalized BT-1 could potentially deliver toxin into target cells 
and induce apoptosis.
the MFI was lower compared with non-biotinylated 2A2-IgG. 
To further rule out the possibility that bound mAb dissociated 
from the cell surface during incubation at 37°C, we used fluoro-
chrome (Atto-488) conjugated 2A2-IgG (Atto-488-2A2-IgG). 
This allowed simultaneous visualization of internalized (direct 
fluorescence) and surface retained (indirect fluorescence) mAb in 
non-permeabilized cells. Direct measurement of Atto-488 signals 
in JeKo-1 cells remained the same before and after incubation 
at 37°C. This is because both the internalized and cell surface 
retained antibody molecules are detected simultaneously, sug-
gesting there was no dissociation of bound mAb. By contrast, 
indirect measurement using a fluorochrome-conjugated second-
ary antibody (Dy-GaM) detects only Atto-488-2A2-IgG retained 
on the cell surface in non-permeabilized cells. As expected, there 
was a clear reduction in signal upon 37°C incubation (Fig. 3A), 
Figure 2. Cell surface binding of 2A2-IgG and Bt-1. primary CLL (A) primary MCL (B) cells and B cell lines (C) were incubated with 1 μg/mL 2A2-IgG or 
Bt-1 (D). In parallel controls, cells were incubated with 1 μg/mL mouse IgG (mIgG) or rabbit IgG (rIgG). (D) three B cell lines (JeKo-1, Mino and RGC-eBV) 
and primary CLL cells from a representative patient were incubated with different amounts of Bt-1. Cell surface bound antibodies were detected using 
Dy-GaM (for mIgG and 2A2-IgG) or RapeA followed by Dy-GaR (for Bt-1). In (A and B), each data point represents an individual patient sample.
Table 1. Binding kinetics and thermodynamics of 2A2-IgG and Bt-1
Ligand Analyte Binding kon [105 s-1M-1] koff [10-4 s-1] Observed KD [10-9 M]
hRoR1-eCD (direct) 2A2-IgG Bivalent 15.2 1.8 0.12
Fc-hRoR1 (direct) 2A2-IgG Bivalent 8.1 3.4 0.42
2A2-IgG (captured) Fc-hRoR1 Bivalent 2.3 1.8 0.79
2A2-IgG (captured) hRoR1-eCD Monovalent 2.4 77.7 32.6
Fc-hRoR1 (direct) Bt-1 Monovalent 5.7 371.4 64.9
the indicated ligands were either directly immobilized on a CM5 chip (rows 1, 2 and 5) or captured with rabbit anti-mouse IgG-Fc pAbs as detailed in 
Materials and Methods. the association (kon), dissociation (koff) rate constants and the observed equilibrium dissociation constant (KD) of the interac-
tions were calculated using the Biacore X100 evaluation software.©2 0 1 1   L a n d e s   B i o s c i e n c e .
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To further confirm BT-1 as a targeted drug, four MCL cell 
lines expressing different levels of ROR1 (HBL-2, JeKo-1, Mino 
and Rec-1) were cultured in the absence or presence of different 
amounts of BT-1 (0.001–100 μg/mL) for three days. Four ROR1-
negative cell lines (RGC-EBV, Daudi, Raji and 232-B4) served 
as controls. Based on Annexin-V binding, all ROR1-positive cell 
lines showed a dose-dependent increase in apoptosis and none of 
the ROR1-negative cell lines showed significant apoptosis over 
background (Fig. 6). The sensitivity to BT-1-induced apopto-
sis appeared to be influenced by target antigen density (ROR1 
expression levels) on the MCL cell lines (Table 2). The HBL-2 
cells had the highest ROR1 expression (based on both MFI and 
Induction of apoptosis by BT-1. Three inde-
pendent assays were performed to determine the 
ability of BT-1 to kill target cells. First, cell sur-
face exposure of PS was detected by Annexin-V 
binding and was interpreted as a measure of 
apoptosis. ROR1-positive (JeKo-1) and ROR1-
negative (Daudi and Raji) cell lines were incu-
bated at 37°C in the absence or presence of 
different amounts of BT-1 (0.01–100 μg/mL) for 
20, 46, 64 and 75 h. While BT-1 induced dose 
and time dependent killing (apoptosis) of JeKo-1 
cells, Daudi and Raji cells were not killed (Fig. 
4S). Similarly, another ROR1-positive cell line, 
HBL-2 exhibited 100% apoptosis when cultured 
with as little as 1 μg/mL (16 nM) BT-1 for three 
days, and the ROR1-negative cell line, RGC-
EBV showed no increase from the background 
level of apoptosis when cultured with up to 100 
μg/mL (1,600 nM) of BT-1 for three days (Fig. 
4). As expected, the untargeted small molecule 
drug camptothecin was able to induce apoptosis 
in all cell lines regardless of ROR1 expression, 
indicating that ROR1-negative cell lines are not 
refractory to apoptosis (data not shown).
Second, change in the mitochondrial mem-
brane potential was measured as an indicator 
of apoptosis. HBL-2 and RGC-EBV cell lines 
were cultured for 24 h in the absence or presence 
of 1 μg/mL BT-1 and subsequently incubated 
with 12.5 nM DiOC2(3) and washed before 
flow cytometry. A drop in the red fluorescence 
intensity (as well as green fluorescence inten-
sity, data not shown), which indicated a change 
in mitochondrial membrane potential (ΔmΨ), 
was noted in HBL-2 cells when cultured with 
BT-1, but not in RGC-EBV cells (Fig. 5A and 
C). Lower concentrations of BT-1 (0.01–0.1 μg/
mL) induced a lower drop of fluorescence inten-
sity in HBL-2 cells (data not shown). Addition 
of 50 μM carbonylcyanide-3-chlorophenylhy-
drazone (CCCP), a nonspecific mitochondrial 
membrane destabilizer, during incubation with 
DiOC2(3) served as a positive control and it 
induced change in mitochondrial membrane 
potential in both cell lines regardless of the presence of BT-1 
(data not shown).
Third, intracellular activated caspase-3 was detected as an 
early indicator of apoptosis. HBL-2 and RGC-EBV cells were 
cultured 24 h in the absence or presence of 1 μg/mL BT-1, and 
subsequently stained with a rabbit mAb against human activated 
caspase-3. Almost all HBL-2 cells cultured with BT-1 exhibited 
the presence of activated caspase-3, whereas RGC-EBV cells 
showed only background levels of staining except for a small 
population of cells (Fig. 5B and D). Collectively, these results 
demonstrated that BT-1 induced apoptosis in the ROR1-positive 
HBL-2 cell line.
Figure 3. RoR1-mediated internalization of cell surface bound antibodies. (A) JeKo-1 
cells were incubated for 1 h at 4°C with 1 μg/mL mIgG, 2A2-IgG, biotin-2A2-IgG or Atto 
488-2A2-IgG. Cells in each group were washed and divided into three aliquots for further 
incubation at 4°C (partly hashed bars), or at 37°C in the absence (black bars) or presence 
(fully hashed bars) of 10 μM pAo. the antibody retained on the surface was detected 
with Dy-GaM (for mIgG and 2A2-IgG) or SA-pe (for biotin-2A2-IgG). the Atto 488-2A2-
IgG binding was detected either by direct fluorescence or indirectly using Dy-GaM. As a 
control, Atto 488-mIgG was used, and gave a background staining of MFI = 3.7 (direct) and 
6.1 (indirect). (B and C) MCL cell lines (JeKo-1 and Mino) and primary CLL cells (data from a 
representative patient is shown) were incubated at 4°C for 1 h with 1 μg/mL 2A2-IgG (B) 
or Bt-1 (C). open bars depict controls incubated with mIgG (B) or rIgG (C). Aliquots were 
made and subsequently incubated at 37°C as described above and the antibody retained 
on cell surface was detected with Dy-GaM (B) or Dy-GaR (C).©2 0 1 1   L a n d e s   B i o s c i e n c e .
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and MCL cells as well as MCL cell lines and revealed the over-
all strongest reactivity with hROR1 and mROR1. Nonetheless, 
2A2-IgG alone or after conversion to chimeric mouse/human 
IgG1 (data not shown) and three chimeric rabbit/human IgG1 
against ROR1 30 failed to induce significant direct cytotoxicity, 
CDC or ADCC in primary CLL cells or ROR1-positive MCL 
cell lines. Such unarmed mAb-mediated effector functions have 
generally been demonstrated in cells with high target antigen 
density (e.g., CDC activity of rituximab on human B cells with 
>40,000 CD20 molecules/cell).37 Our previous study estimated 
the ROR1 density on CLL cells to be between 2,500 and 7,000 
molecules/cell,9 which may be below the threshold needed for 
unarmed mAbs to mediate effector functions.38,39 It is also pos-
sible that the effector functions of unarmed mAbs against ROR1 
are influenced by epitope location.40
Knowing that cell surface ROR1 mediated internalization 
of bound antibody in primary CLL cells and MCL cell lines, 
the use of a ROR1-immunotoxin was sought to potentially over-
come this limitation. The induction of profound apoptosis by 
mAb 2A2-derived ROR1-immunotoxin BT-1 in dsFv-PE38 for-
mat in ROR1-positive MCL cell lines, but not in ROR1-negative 
B-cell lines validated that ROR1 can function as a therapeutic 
target. The specific cytotoxicity induced by BT-1 was confirmed 
by three independent measurements: PS exposure to cell surface, 
change in mitochondrial membrane potential and activation of 
caspase-3, events that have been well documented in apoptotic 
ABC values) and the EC50 of BT-1 was approximately 0.01 μg/mL   
(0.16 nM), followed by JeKo-1 at 0.1 μg/mL (1.6 nM) and Mino 
at 1.0 μg/mL (16 nM). The Rec-1 cells were highly sensitive 
to BT-1 EC50 0.001 μg/mL (0.016 nM), but there was a dis-
crepancy in the measurement of ROR1 expression. In repeated 
experiments, while the MFI values were low (Fig. 2C), the ABC 
values were high (Table 2) for Rec-1 cells and the reason for this 
inconsistency is not known. Next, as an independent correlate, 
the level of the anti-apoptotic protein, BCL2 was measured. The 
amount of intracellular BCL2 varied among the ROR1-positive 
MCL cell lines, and paralleled their sensitivity to BT-1 (Table 2). 
It is interesting to note that the highly sensitive Rec-1 cells have 
the lowest BCL2 level.
Discussion
Targeted therapy is a novel approach in the treatment and control 
of cancers, and has the potential to enhance the therapeutic effi-
cacy, minimize undesirable side effects and help achieve a better 
clinical outcome in patients. With respect to B-cell malignancies, 
we and others have demonstrated uniform and restricted expres-
sion of ROR1 in CLL and MCL cells, and suggested its potential 
as a therapeutic target.9-11,36 The present study describes the devel-
opment, characterization and validation of four mouse mAbs 
against hROR1. Subsequently, we focused on one of the two mAbs 
(2A2-IgG) that selectively bound ROR1-positive primary CLL 
Figure 4. Bt-1-induced apoptosis in RoR1-positive cells. A RoR1-positive (HBL-2) and a RoR1-negative (RGC-eBV) cell line were cultured in the absence 
(medium alone) or presence of Bt-1 at 1 μg/mL and 100 μg/mL, respectively, for 3 d at 37°C. Apoptotic cells were detected with Annexin-V staining.©2 0 1 1   L a n d e s   B i o s c i e n c e .
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estimated cell surface retention of BT-1 would be 19 sec com-
pared with 34 min for 2A2-IgG. Although the dose-response 
curves with BT-1 showed robust killing of ROR1-positive 
MCL lines at low concentration (with EC50 values of 16 pM to   
16 nM), there is likely room for improvement. Other PE38-
based immunotoxins that target different antigens on malig-
nant B cells (CD19 and CD22) or mesothelioma (mesothelin) 
showed higher potency presumably due to higher affinity, i.e., 
lower dissociation rate constants, for the respective antigens, 
resulting in longer cell surface retention.41 Currently, we are 
looking into different antibody engineering strategies to improve 
the affinity or avidity of BT-1. Alternatively, a new panel of chi-
meric rabbit/human mAbs to ROR1 that was selected by phage 
display in the monovalent Fab format for high affinity binding 
to ROR1 and reveals dissociation rate constants up to 120-fold 
cell death. The maximum effect was seen after approximately 3 d 
and this is in agreement with other studies using PE38-based 
immunotoxins.16 The dose-response curves depicted differences 
in BT-1 sensitivity among different MCL cell lines, and this could 
reflect cell specific intrinsic factors as regulators of apoptosis.
A number of parameters determine the efficacy of immu-
notoxins. First, the affinity of a mAb or a mAb fragment (e.g., 
dsFv) to its target antigen largely determines the stability of 
the antibody/antigen complex on the cell surface. A head-to-
head comparison of the observed KD values of bivalent 2A2-IgG 
(0.42 nM) and 2A2-derived monovalent BT-1 (64.9 nM) bind-
ing to immobilized Fc-ROR1 revealed an approximately 150-
fold difference in BT-1 binding. Assuming that similar binding 
might occur with cell surface ROR1 and given that the half-
life of the antigen/antibody interaction equals ln2/koff, the 
Figure 5. early events of apoptosis induced by Bt-1. HBL-2 (A and B) or RGC-eBV (C and D) cells were cultured in the absence (open histogram) or 
presence (filled histogram) of Bt-1 at 1 μg/mL for 24 h at 37°C. For measuring the mitochondrial membrane potential, ΔmΨ (A and C), the cells were 
washed in warm medium and incubated with 12.5 nM DioC2(3) in DMSo or DMSo alone for 30 min at 37°C. Separate tubes were set up as positive 
control where 50 μM CCCp in DMSo was added along with DioC2(3). All cells were washed once before flow cytometry. the x-axis represents DioC2(3) 
fluorescence intensity = ΔmΨ. For intracellular staining for activated caspase-3 (B and D), separate tubes were set up, and the cells were permeabi-
lized, fixed and stained with pe-conjugated rabbit anti-human activated caspase-3 antibody. In (D), the open and filled histograms are superimposed. 
the data obtained in a representative experiment is shown.©2 0 1 1   L a n d e s   B i o s c i e n c e .
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paralleled ROR1 expression levels among these cell lines. A cor-
relation between target antigen density and apoptosis induction 
was also reported for CD22- and FCRL1-immunotoxins.16,42 
However, preliminary results indicate that Rec-1 cells expressed 
the lowest level of the anti-apoptotic protein BCL2 compared 
with the other MCL cell lines we tested. It is conceivable that 
BCL2 levels in addition to the level of other anti-apoptotic pro-
teins (e.g., MCL1, survivin, X1AP) can influence the efficacy of 
BT-1 as has been reported for other immunotoxins.43,44
Third, our epitope mapping studies indicated that 2A2-IgG 
(the parent antibody of BT-1) bound to the membrane distal 
Ig-domain of ROR1. Immunotoxins generated from antibodies 
recognizing different epitopes on the same antigen showed signif-
icant differences in their potency in vitro.45,46 An immunotoxin 
binding to a membrane proximal epitope on the target antigen, 
CD2, induced higher cytotoxicity than those binding to distal 
epitopes.47 Therefore, it may be worthwhile to generate ROR1-
immunotoxins based on mAbs recognizing different epitopes and 
compare their abilities to kill ROR1-expressing cells.
Fourth, the rate of internalization of surface bound immu-
notoxin could affect its efficacy. A recent study compared the 
efficacy of two immunotoxins, RFB4 (Fv)-PE38 also known 
as BL22 (anti-CD22) and FMC63 (Fv)-PE38 (anti-CD19) on 
lower than BT-1,30 could be employed for the next generation of 
ROR1-immunotoxins.
Second, the target antigen density on the cell surface could 
influence immunotoxin efficacy. Our data showed an approxi-
mately 1000-fold difference in EC50 values among ROR1-
positive MCL cell lines (0.016 nM for Rec-1, 0.16 nM for HBL-2,   
1.6 nM for JeKo-1 and 16 nM for Mino) and overall this 
Figure 6. Immunotoxin induced dose-dependent apoptosis in MCL cell lines. Four RoR1-positive MCL cell lines (filled symbols; HBL-2, blue square; 
JeKo-1, red triangle; Mino, green triangle; Rec-1, black circle) and four RoR1-negative B cell lines (open symbols; RGC-eBV, blue square; Daudi, red 
triangle; Raji, green triangle; 232-B4, black circle) were cultured in the absence or presence of different amounts of Bt-1 (1 ng/mL–100 μg/mL) for 3 d at 
37°C. the percentage of apoptotic cells was determined by Annexin-V staining. the data presented is representative of three independent experi-
ments.
Table 2. RoR1 expression levels and Bt-1 sensitivity
Target cells
BCL2a 
(MFI)
ROR1b 
(ABC)
BT-1 sensitivity EC50 [nM]c
HBL-2 78 25440 0.16
JeKo-1 29 12484 1.6
Mino 41 10144 16
Rec-1 18 27386 0.016
aIntracellular BCL2 expression was determined using a pe-conjugated 
mouse anti-human BCL2 mAb; pe-conjugated isotype control was used 
for background staining. bRoR1 density was determined by measuring 
ABC of 2A2-IgG-AlexaFluor-647; polyclonal mIgG-AlexaFluor-647 was 
used as control. cConcentration of Bt-1 required to induce apoptosis 
in 50% of the cells. Similar values were obtained in three independent 
experiments.©2 0 1 1   L a n d e s   B i o s c i e n c e .
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and Burkitt lymphoma cell lines (Raji, Ramos and Daudi) were 
obtained from ATCC. EBV-transformed lymphoblastoid cell 
lines were generated from PBMC from a healthy donor (EBV-
7475) and a patient with CLL (RGC-EBV) by following stan-
dard procedure;29 both of these were oligoclonal suggesting their 
origin from normal B cells (unpublished observation). All cell 
lines were maintained in vitro in RPMI-1640 supplemented 
with 2 mM Glutamax, 10% (v/v) (GIBCO, 61870) fetal bovine 
serum (FBS) (GIBCO, 10437), 20 mM HEPES (GIBCO, 
15630080), 100 IU/mL penicillin, 100 μg/mL streptomycin sul-
fate (GIBCO #15140-148), 50 μM β-mercaptoethanol (Sigma, 
M-7522) and 1 mM sodium pyruvate (GIBCO, 11360070).
Mouse mAbs against human ROR1. A panel of recombinant 
ROR1 proteins were cloned, expressed and purified as described 
in reference 30; Fc-hROR1, hROR1-ECD, Fc-hROR1Ig+Fz 
(Ig+Fz), Fc-hROR1Fz+Kr (Fz+Kr), Fc-hROR1Ig (Ig), 
Fc-hROR1Fz (Fz), Fc-hROR1Kr (Kr), human Fc (Fc) and 
Fc-mROR1. Purified human ROR2-Fc was purchased from 
R&D Systems (custom order).
Mouse anti-hROR1 mAbs were custom generated (Precision 
Antibody). In brief, mice were immunized with Fc-hROR1, and 
after three booster injections with hROR1-ECD serum anti-
body response against ROR1 was detected. Hybridomas were 
generated using the immune spleen cells. Screening of about 
100 hybridoma clones yielded four clones 2A2, 2D11, 1A1 and 
1A7 that secreted mAbs that bound specifically to ROR1. The 
four hybridoma clones were grown in BD Cell mAb medium 
(Animal Component Free, Becton Dickinson, 220513) using 
CELLine Flasks (Becton Dickinson, 353137) and supernatants 
were collected. HiTrap Protein G columns (GE Healthcare, 
17-0404-01) were used to purify immunoglobulins (Ig) from 
the supernatants. Reduced SDS-PAGE analysis revealed only Ig 
heavy and light chain bands of expected molecular sizes for each 
mAb. The isotype of all four mAbs was determined to be mouse 
IgG1kappa using the Mouse Immunoglobulin Isotyping ELISA 
Kit (BD Pharmingen, 550487).
Preparation of ROR1-immunotoxin. Partial amino acid 
sequences from both variable domains of 2A2-IgG were obtained 
by custom LC-MS/MS analysis on tryptic digests of SDS-PAGE 
resolved heavy and light chain polypeptides (Alphalyse, custom 
order). Based on this information, the mouse V gene fami-
lies were identified using Ig BLAST (www.ncbi.nlm.nih.gov/
igblast). Oligonucleotides aligning to the signal peptide encod-
ing DNA sequences of the Vκ and VH gene families and to the 
Cκ and Cγ11 constant domain encoding DNA sequences were 
used to amplify 2A2-VL and 2A2-VH by RT-PCR from total 
RNA isolated from 2A2 hybridoma cells. DNA sequencing of 
the PCR products yielded the complete amino acid sequences 
of the 2A2-VH and 2A2-VL polypeptides (International Patent 
Application PCT/US2010/032208). The 2A2-based immuno-
toxin BT-1 was generated following the procedure described 
in reference 31 with some changes detailed below. Optimized 
for expression in Escherichia coli (E. coli), the DNA sequences 
encoding 2A2-VH and 2A2-VL polypeptides were custom syn-
thesized with the following modifications (DNA 2.0); 2A2-VH 
included a NdeI site at the 5' end and a HindIII site at the 3' 
lymphoma cell lines. Despite lower cell surface expression of 
CD22, rapid internalization of large amounts of BL22 made 
CD22 a better target than CD19 present in high density.48 There 
was clear evidence for BT-1-mediated apoptosis in ROR1-positive 
cell lines within 24 h, but how much BT-1 was actually internal-
ized is unknown. Further studies on the membrane dynamics 
of ROR1, intracellular trafficking of BT-1 and its degradation 
rate are required to better understand and improve the efficacy of 
next generation ROR1-immunotoxins.
Despite the profound cytotoxicity induced by BT-1 in vitro, 
the surface plasmon resonance data indicated relatively fast dis-
sociation of the monovalent BT-1 compared with its parent anti-
body, and it is likely that this could be a limitation in exploring 
its in vivo activity. We are currently working on generating dif-
ferent formats of ROR1 immunotoxins with a goal to enhance 
the affinity/avidity, and minimize potential immunogenicity. 
The efficacy of improved immunotoxins can be tested in vivo 
using MCL cell lines as xenografts in nude mice. The cytotox-
icity studies described here were based on MCL cell lines and, 
unlike primary CLL and MCL cells, they do not undergo spon-
taneous apoptosis in vitro. A more clinically relevant system for 
evaluating the ability of ROR1-immunotoxins to kill primary 
CLL and MCL cells may be a recently developed mouse model 
with adoptively transferred human primary CLL cells that retain 
ROR1 expression in vivo.49
In summary, as a proof of concept, we have demonstrated that 
a ROR1-immunotoxin can induce apoptosis resulting in robust 
killing of ROR1-expressing MCL cell lines in vitro. Owing to 
its exquisite specificity, BT-1 could function as a leukemia/lym-
phoma specific therapeutic agent in vivo, and unlike unarmed 
mAbs, would not depend on the effector machinery such as 
complement proteins, NK cells, macrophages or T cells as these 
may not be optimally available in cancer patients. BT-1 provides a 
platform for next generation ROR1-immunotoxins with defined 
modifications in both antibody and toxin portion designed to 
enhance affinity and efficacy, as well as minimize immunogenic-
ity.50,51 In addition, combination strategies with small molecule 
inhibitors of anti-apoptotic proteins could help to mitigate the 
opposing effects and boost the efficacy of BT-1 and next genera-
tion ROR1-immunotoxins.
Materials and Methods
Patient samples and cell lines. Patients with CLL and MCL 
were enrolled in institutional review board-approved studies at 
the National Institutes of Health (NIH), Bethesda, MD and 
blood samples were obtained with written informed consent. 
Blood samples from healthy donors were obtained from the 
Department of Transfusion Medicine, Clinical Center, NIH. 
Peripheral blood mononuclear cells (PBMC) were prepared by 
density gradient separation of whole blood on lymphocyte sepa-
ration medium (MP Biochemicals, 50494) and cryopreserved 
until use. The CLL cell lines MEC-1 and MEC-2 were obtained 
from DSMZ and 232-B4 was a gift from Dr. Anders Rosén 
(Linköping University). The MCL cell lines used in this study 
(JeKo-1, HBL-2, Mino and Rec-1) have been characterized,28 ©2 0 1 1   L a n d e s   B i o s c i e n c e .
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bound antibody was determined by adding the HRP substrate 
ABTS (Roche Applied Science, 10102946001) and measuring 
the absorbance at 405 nm (and 490 nm to allow auto correction) 
in a VersaMax microplate reader (Molecular Devices).
Surface plasmon resonance. The binding kinetics of anti-
hROR1 antibody formats (2A2-IgG and BT-1) and hROR1 
were studied by measuring the surface plasmon resonance using 
a Biacore X-100 instrument and Biacore reagents and software 
(GE Healthcare). This was done either by direct coupling or 
capture of the ligands at comparable and low densities to mini-
mize the mass transfer effect. For direct coupling, a CM5 sensor 
chip (GE Healthcare, BR-1000-12) was activated with 1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide hydrochloride and 
N-hydroxysuccinimide for subsequent ligand immobilization. 
The fusion proteins Fc-hROR1 and hROR1-ECD in 10 mM 
sodium acetate pH 5.0 were immobilized in flow cell 1 (FC-
1) at a density of 160–300 resonance units (RU) in separate 
sensor chips. The FC-2 in each chip served as control (without 
ligand) to allow instant background correction. The chips were 
deactivated with 1 M ethanolamine hydrochloride, pH 8.5. The 
analytes, 2A2-IgG and BT-1, were diluted in 1x HBS-EP+ run-
ning buffer pH 7.4 (10 mM HEPES, 150 mM NaCl, 3 mM 
EDTA and 0.05% (v/v) Surfactant P20), and five different con-
centrations of analytes (range 2.5–100 nM) were run in dupli-
cates at a flow rate of 30 μL/min. The chips were regenerated 
using glycine-HCl pH 2.0 without significant loss of binding 
capacity. In the capture method, first polyclonal rabbit anti-
mouse IgG was immobilized on a CM5 chip to give an approxi-
mate final density of 9,790 RU in both FC-1 and FC-2 (Mouse 
Antibody Capture Kit; GE Healthcare, BR-1008-38) and deac-
tivated following the manufacturer’s recommended procedure. 
Subsequently, the ligand (2A2-IgG) was captured at 1 μg/mL 
(predetermined concentration) to give an approximate density 
of 200 RU in FC-1, with FC-2 serving as control. The ana-
lytes (hROR1-ECD and Fc-hROR1) were run at five different 
concentrations (range 3–1,000 nM) in duplicates as described 
above. Calculation of association (kon) and dissociation (koff) rate 
constants was based on a 1:1 Langmuir binding model for both 
monovalent and bivalent interactions. The equilibrium dissocia-
tion constant (KD) was calculated from koff/kon.
Flow cytometry. Approximately 5 × 105 cells were incubated 
with different concentrations of affinity-purified 2A2-IgG or 
normal polyclonal mouse IgG (mIgG; Jackson ImmunoResearch 
Laboratories, 015-000-003) for 45 min at 4°C. After two washes 
with FACS buffer (2% (v/v) FBS in PBS pH 7.2), the cells were 
incubated for 45 min at 4°C with DyLight-649 conjugated, affin-
ity pure F(ab)2 preparation of goat anti-mouse IgG (Dy-GaM; 
Jackson ImmunoResearch Laboratories, 115-496-146) or APC-
conjugated goat anti-mouse IgG, Fc fragment specific (APC-
GaM, 115-136-071) at 1:500 final dilution. For primary CLL 
and MCL cells, the malignant B cells were gated using CD5/
CD19 Simultest reagent (BD Biosciences, 340396). Similarly, 
for staining with ROR1-immunotoxin BT-1, target cells were 
incubated with various concentrations of BT-1, followed by 
normal polyclonal rabbit IgG (rIgG, Jackson ImmunoResearch 
Laboratories, 011-000-002) or the secondary antibody (RaPEA) 
end; 2A2-VL included a NdeI site at the 5' end and an EcoRI 
site at the 3' end. In addition, the codons for residues 45 in 
2A2-VH and 99 in 2A2-VL, both present in framework regions, 
were substituted with a codon for cysteine to allow pairing of 
VH and VL polypeptides and yield disulphide linked Fv (dsFv) 
after refolding. These DNA sequences were cloned into sepa-
rate stocks of pJ201 plasmids. NdeI/HindIII-digested 2A2-VH 
was cloned into a T7 expression vector (pRB98) creating an 
in-frame fusion with a DNA sequence encoding truncated 
Pseudomonas exotoxin A (PE38). Separately, NdeI/EcoRI-
digested 2A2-VL was cloned into pRB98 (thereby removing the 
PE38 encoding DNA sequence).31 The two expression plasmids 
were separately electroporated into E. coli strain BL21 (λDE3) 
cells (ElectroMax; Invitrogen, 11319-019) and 1 L culture of 
bacteria transformed with each plasmid was grown with IPTG 
induction. The bacterial pellets were processed and inclusion 
body proteins were pooled and allowed to refold. The refolded 
ROR1-immunotoxin, 2A2(dsFv)-PE38 (named BT-1), was 
purified by two sequential ion exchange chromatography steps 
using Q-Sepharose column (GE Healthcare, 17-5159-01) and 
Mono-Q column (GE Healthcare, 17-5166-01) followed by a gel 
filtration chromatography step using a HiLoad 16/60 Superdex 
S200 prep grade column (GE Healthcare, 17-1069-01), all in 
conjunction with an ÄKTA-FPLC system using Unicorn soft-
ware (Amersham Pharmacia Biotech). The purity of BT-1 was 
validated by a single sharp peak seen in the gel filtration chroma-
tography profile, its retention time was in close proximity with 
that of bovine serum albumin (BSA, Sigma-Aldrich, A-7906) 
in the same column, and SDS-PAGE analysis revealed a single 
band of the expected size (Fig. S2). Purified BT-1 was stored in 
PBS pH 7.2 at -70°C until use.
Enzyme-linked immunosorbent assay (ELISA). To deter-
mine the specific reactivity and epitope mapping of anti-ROR1 
mAbs, 96-well plates (Clear Microplate; R&D Systems, DY990) 
were coated with indicated recombinant ROR1 proteins (100 
ng in 50 μL/well) in PBS pH 7.2 overnight at 4°C. The next 
day, the wells were washed with 10 mM Tris-buffered saline 
with 0.1% (v/v) Triton X-100 pH 7.2 (TBST) using an auto-
matic plate washer (Beckman Coulter), and blocked with 300 
μL/well 3% (w/v) BSA in PBS pH 7.2 for 2 h at 25°C. After 
one wash cycle, 50 μL of primary anti-ROR1 antibodies (mouse 
mAbs 2A2-IgG, 2D11-IgG, 1A1-IgG, 1A7-IgG, goat polyclonal 
antibodies (pAbs) against ROR1 (R&D Systems, AF2000), goat 
pAbs against ROR2 (R&D Systems, AF2064) or BT-1) diluted 
in 1% (w/v) BSA in PBS pH 7.2 were added in different concen-
trations and incubated at 25°C for 2 h. For BT-1 alone, the wells 
were washed again, 50 μL/well polyclonal rabbit anti-pseudo-
monas exotoxin A serum (RaPEA, Sigma-Aldrich, P2318) was 
added at 1:300 final dilution and incubated for 2 h. After two 
wash cycles, 50 μL/well corresponding detection antibodies were 
added (horseradish peroxidase conjugated donkey anti-mouse 
IgG, DaM-HRP (Jackson ImmunoResearch Laboratories, 715-
036-150); donkey anti-goat IgG, DaG-HRP (705-035-147) or 
donkey anti-rabbit IgG, DaR-HRP (711-036-152) at 1:1,000 
dilution in 1% (w/v) BSA in PBS pH 7.2 and incubated for 
1 h at 25°C. After two wash cycles, the enzymatic activity of ©2 0 1 1   L a n d e s   B i o s c i e n c e .
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incubated for 30 min at 4°C in the dark with predetermined 
saturating concentration of 2A2-IgG-AF647. As control, mIgG-
AF647 was used. In parallel, the quantum beads were incubated 
with predetermined saturating concentration of 2A2-IgG-AF647 
conjugate. The cells and the beads were washed three times, 
resuspended in the FACS buffer and the MFI were determined 
by flow cytometry with the same instrument settings. Using the 
QuickCal software (Bangs Laboratories), a calibration curve 
was generated by plotting MFI vs. the antigen binding capac-
ity (ABC) of the beads. The delta MFI values of each sample 
(2A2-IgG-AF647 minus mIgG-AF647) was used to determine 
the ABC of the sample and considered to represent the antigen 
(ROR1) density on the cell surface.
Immunotoxin-mediated cytotoxicity. ROR1-immunotoxin 
(BT-1) induced death of target cells was detected by three 
independent methods: (a) detection of cell surface exposure of 
phosphatidylserine (PS),32 (b) measurement of changes in mito-
chondrial membrane potential33 and (c) intracellular detection 
of activated caspase-3.34,35 ROR1-expressing and non-expressing 
cell lines (2.5 × 105 cells) were incubated at 37°C for various 
periods of time in RPMI-5% (v/v) FBS in the absence or pres-
ence of different amounts of BT-1 (0.01–100 μg/mL). For PS 
exposure, both BT-1 treated and untreated cells were washed 
in Annexin-V binding buffer (ABB), incubated with Alexa 
Fluor 647-conjugated Annexin-V (Invitrogen, A23204) and 
SYTOX Green (Invitrogen, S7020) following the manufac-
turer’s recommended procedure and subjected to flow cytom-
etry. Camptothecin (Sigma-Aldrich, C9911) was used (10 
μM) as a positive control to induce apoptosis. The percentage 
of apoptotic cells was determined as follows: % Apoptosis = % 
Annexin-V-positive cells + % Annexin-V-positive and SYTOX 
Green-positive cells/total cells analyzed × 100. The SYTOX 
Green-positive and Annexin-V-negative cells were considered 
necrotic cells, and the double negative cells were considered live 
cells. The change in mitochondrial membrane potential (ΔmΨ) 
has been considered to be one of the early events in apopto-
sis, and such a change leads to accumulation of cationic cyanine 
dyes in cells that can be measured by flow cytometry. Untreated 
and BT-1 treated cells were incubated with a predetermined 
concentration (12.5 nM) of 3,3'-diethyloxacarbocyanine iodide 
(DiOC2(3); MitoProbe kit, Molecular Probes, M34150) fol-
lowing the manufacturer’s recommended procedure. The cells 
were washed once and red and green fluorescence intensities 
were measured. Red fluorescence intensity increases due to dye 
stacking in cells with active mitochondria and decreases in cells 
with disrupted mitchondria. Both qualitative and quantitative 
changes in fluorescence intensity of the dye were measured and 
depicted as histogram. The caspase family of cysteine proteases 
plays a key role in apoptosis. In particular, caspase-3 is activated 
during early stages of apoptosis, and the active enzyme cleaves 
survival proteins such as BCL2 and PARP, resulting in apop-
tosis. To determine intracellular levels of activated caspase-3, 
BT-1 treated and untreated cells were washed in PBS, fixed and 
permeabilized using BD Cytofix/Cytoperm for 20 min at 25°C, 
washed with BD Perm/Wash buffer. Cells were then stained 
at 1:300 final dilution and then with DyLight-649-conjugated, 
affinity pure F(ab)2 preparation of goat anti-rabbit IgG (Dy-GaR; 
Jackson ImmunoResearch Laboratories, 111-496-144) at 1:500 
final dilution. Cells were washed twice with FACS buffer in each 
step and, after two final washes, they were resuspended in FACS 
buffer and 5 μg/mL propidium iodide (P.I., Sigma-Aldrich, 
P4170) was added to exclude dead cells from analysis. For the 
detection of intracellular BCL2, the cells were washed in PBS, 
then with BD Perm/Wash buffer (BD Biosciences, 554723), 
and subsequently fixed and permeabilized for 20 min using BD 
Cytofix/Cytoperm buffer (BD Biosciences, 554722) and washed 
again with BD Perm/Wash buffer. The cells were stained with 
PE-conjugated mouse anti-human BCL2 mAb or an isotype 
control (BD Biosciences, BCL2 set #556535). A total of 20,000 
gated events were collected for each sample using FACSCalibur 
instrument (BD Biosciences) and data were analyzed using 
CellQuest software. The values were depicted as mean fluores-
cence intensity (MFI).
ROR1-mediated internalization of mAbs. ROR1-mediated 
internalization was determined by measuring the decrease in sur-
face bound (at 4°C) anti-ROR1 mAb after incubation at 37°C.9 
Approximately 2 × 106 target cells were incubated with 1 μg/mL 
unconjugated 2A2-IgG for 1 h on ice (4°C) in RPMI-5% (v/v) 
FBS. The cells were washed twice with ten volumes of medium 
and resuspended as 5 × 105 aliquots in medium. One aliquot 
was left on ice and the others were incubated at 37°C for vari-
ous periods of time either without or with 10 μM phenylarsine 
oxide (PAO; Sigma-Aldrich, P3075). Next, the cells were washed 
with medium and all samples were incubated with Dy-GaM 
at 1:500 final dilution. After 1 h incubation on ice, the cells 
were washed and resuspended in FACS buffer (see above) with   
5 μg/mL P.I. and analyzed by flow cytometry. Additional exper-
iments were performed using biotinylated 2A2-IgG prepared 
with the BiotinTag Microbiotinylation kit (Sigma-Aldrich, 
BIOTAG), and detected by streptavidin-conjugated phycoery-
thrin (SA-PE, BD Biosciences, 554061). Furthermore, directly 
labeled 2A2-IgG was used to simultaneously measure cell surface 
bound and internalized antibody. For this, mIgG (as control) 
and 2A2-IgG were coupled to Atto-488 following the manufac-
turer’s recommended procedure (Novus Biologicals, 733-0010). 
While Atto488 fluorescence collectively measured cell surface 
bound and internalized 2A2-IgG, only the cell surface bound 
fraction was detectable with a secondary antibody (Dy-GaM) in 
non-permeabilized cells. Internalization of BT-1 was analyzed 
by sequential incubations with RaPEA and Dy-GaR (Jackson 
ImmunoResearch Laboratories, 111-496-144) as described 
above.
Determination of ROR1 density. The number of ROR1 
molecules on the target cell surface was determined using the 
Quantum Simply Cellular Microbeads Kit (Bangs Laboratories, 
815B) as described before in reference 9, with following modi-
fications. First, 2A2-IgG was directly labeled using Alexa Fluor 
647 Protein Labeling Kit (Molecular Probes, A20173) follow-
ing the recommended procedure to obtain 2A2-IgG-AF647 
conjugate. In parallel, polyclonal mouse IgG (mIgG) was used 
to obtain mIgG-AF647. Approximately, 1 × 106 cells were ©2 0 1 1   L a n d e s   B i o s c i e n c e .
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